Type Public Area served Worldwide Website www.novavax.com Number of employees 443 (2016) | Industry Biotechnology Products Vaccines CEO Stanley C. Erck Founded 1987 | |
 | ||
Traded as NASDAQ: NVAX
S&P 500 Component Stock price NVAX (NASDAQ) US$ 1.34 -0.04 (-2.90%)17 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters Rockville, Maryland, United States Subsidiaries Fielding Pharmaceutical Company, Isconova AB, Cpl Biologicals Pvt. Ltd., Profiles | ||
Novavax ceo biotech bounce back mad money cnbc
Novavax, Inc. is a clinical-stage vaccine company headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is a public company that trades under the symbol "NVAX". In June 2013, Novavax acquired the Matrix-MTM adjuvant platform with the purchase of Swedish company Isconova AB and renamed it Novavax AB.
Contents
- Novavax ceo biotech bounce back mad money cnbc
- Novavax learn how i turned 15 253 into 1 613 442 trading biotech stocks
- Respiratory Syncytial Virus RSV
- References
Novavax learn how i turned 15 253 into 1 613 442 trading biotech stocks
Respiratory Syncytial Virus (RSV)
Novavax is currently pursing an RSV vaccine for infants via maternal immunization and children six months to five years, after the failed trials for its older adult vaccine. The company received an $89 million grant from the Bill & Melinda Gates Foundation to support the development of the RSV-F vaccine for infants via maternal immunization. A Phase 3 clinical trial of the RSV-F vaccine for infants via maternal immunization was initiated in December 2015. The company is also working on flu and Ebola vaccines, but doesn’t have any commercially available products.